格隆汇10月31日｜知情人士透露，在"减肥神药"Ozempic丹麦生产商诺和诺德以更高报价截胡辉瑞对肥 胖药研发公司Metsera的收购后，辉瑞正筹备对Metsera及诺和诺德提起诉讼。辉瑞指出，诺和诺德的报 价虽金额可观但结构复杂（采用两步交易模式），且此前已被Metsera董事会以风险过高为由否决，该 方案既规避监管审批，又不符合"更优提案"标准。此次收购Metsera是辉瑞在放弃减肥药片研发后，跻 身1500亿美元减肥药市场的背水一战。该公司已预演公关策略，将自身与Metsera定位为"美国国家 队"，而将诺和诺德的竞购定义为外资"绞杀式收购"。辉瑞在声明中强调："这是市场垄断企业通过吞并 新兴美国挑战者来压制竞争的非法尝试，已涉嫌违反反垄断法规。" ...

Let's get to Eli Liy here. Surging almost 4% today after a beat and raise uh earnings report thanks to booming demand for its GLP1 drugs zbound in Monjaro. Also an obese obesity Novo Nordisk down 2 and a half% after confirming that it has made an unsolicited bid to acquire Meter better than the offer that Fizer had made last month.Semaphore reporting this afternoon that Fizer is considering a lawsuit against Novo and Metsa over the bid. For more on all of this, Missouo healthcare strategist Jared Holles is ...

Let's get to Eli Liy here. Surging almost 4% today after a beat and raise uh earnings report thanks to booming demand for its GLP1 drugs zbound in Monjaro. Also an obese obesity Novo Nordisk down 2 and a half% after confirming that it has made an unsolicited bid to acquire Meter better than the offer that Fizer had made last month.Semaphore reporting this afternoon that Fizer is considering a lawsuit against Novo and Metsa over the bid. For more on all of this, Missouo healthcare strategist Jared Holles is ...

On 5 November 2025, Novo Nordisk A/S ( NVO ) will announce its Q3 2025 earnings. Given that I've previously conducted a more detailed , and I think it's fair to say, veryI’ve managed my investments since 1999, gaining perspective across multiple market cycles. With a background in Economics and ongoing CFA certification, my focus is on uncovering mispriced assets that the market has overlooked.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, a ...

On 5 November 2025, Novo Nordisk A/S ( NVO ) will announce its Q3 2025 earnings. Given that I've previously conducted a more detailed , and I think it's fair to say, veryI’ve managed my investments since 1999, gaining perspective across multiple market cycles. With a background in Economics and ongoing CFA certification, my focus is on uncovering mispriced assets that the market has overlooked.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, a ...

Novo Nordisk's late bid to hijack Pfizer's takeover of U.S. obesity biotech Metsera marks an aggressive shift from the Danish drugmaker as it seeks to regain ground in the weight-loss drug market unde... ...

By Maggie Fick LONDON (Reuters) -Novo Nordisk's late bid to hijack Pfizer's takeover of U.S. obesity biotech Metsera marks an aggressive shift from the Danish drugmaker as it seeks to regain ground in the weight-loss drug market under a new CEO and board. Novo, the drugmaker behind blockbuster weight-loss drug Wegovy and diabetes treatment Ozempic, launched a bid on Thursday for Metsera valuing the firm at some $9 billion and crashing Pfizer's deal for the firm announced in September. The move, after No ...

Novo Nordisk will pay for its Metsera merger now, even if the merger never happens. (via @opinion) https://t.co/sznol3hu0m ...

TRENDING: You Don't Have To Dig Far To Cash In On Rare Earths Novo Nordisk (NVO) kicked off a new battle with Pfizer (PFE) on Thursday by making an unsolicited $6.5 billion bid for obesity-focused takeover target, Metsera (MTSR). The bid sent shock waves through Wall Street. "You wouldn't have expected a GLP-1 incumbent to be bidding here," Evercore ISI analyst Umer Raffat said in a report to clients. "But you know what the bigger surprise is? That Novo is basically offering a 50% termination fee." Pfizer a ...

Core Viewpoint - Metsera Inc. received an unsolicited acquisition proposal from Novo Nordisk, which it considers a "Superior Company Proposal" under its existing agreement with Pfizer [1][3] Group 1: Acquisition Proposal Details - Novo Nordisk's proposal is structured in two steps, with an initial cash payment of $56.50 per share and additional contingent value rights based on development milestones [2][7] - The total potential value of Novo Nordisk's proposal could reach up to $77.75 per share, equating to approximately $9 billion [3] Group 2: Pfizer's Response - Pfizer has acknowledged Novo Nordisk's proposal, labeling it as "reckless and unprecedented," and claims it aims to suppress competition unlawfully [3][4] - Pfizer intends to pursue all legal avenues to enforce its rights under the existing agreement with Metsera [4] Group 3: Metsera's Board Decision - Metsera's Board previously rejected Novo Nordisk's proposal due to various risks associated with its deal structure, favoring Pfizer for its certainty and expected timeline [5] Group 4: Market Reaction - Following the news, Metsera's stock rose by 21.03% to $63.19, while Novo Nordisk's stock fell by 2.31% to $50.19 [5]